IGF system in cancer: From bench to clinic

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 206-212

  Chaves, Jorge ^a   Saif, Muhammad Wasif ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

cancer; insulin like growth factors; insulin like growth factors binding proteins

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AMG 479; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVE 1642; AXL 1717; BIIB 022; BMS 536924; BMS 554417; BMS 754807; CELL SURFACE RECEPTOR; CIXUTUMUMAB; CYCLOLIGNAN PICROPODOPHYLLIN; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EXEL 228; FIGITUMUMAB; GANITUMAB; GEFITINIB; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; NVP AEW 541; OSI 906; PODOPHYLLIN; PROTEIN TYROSINE KINASE INHIBITOR; ROBATUMUMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CIRCULATING TUMOR CELL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR CELL;

HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; SOMATOMEDINS; TRANSLATIONAL RESEARCH;

EID: 79951678633     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834258a1     Document Type: Review

References (80)

1. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987; 38:223-230. (Pubitemid 18005853)
2. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76:1005-1026. (Pubitemid 26346814)
3. Roberts CTJr, Brown AL, Graham DE, Seelig S, Berry S, Gabbay KH, et al. Growth hormone regulates the abundance of insulin-like growth factor I RNA in adult rat liver. J Biol Chem 1986; 261:10025-10028. (Pubitemid 17221930)
4. Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K. Receptors for insulin and insulin-like growth factor-I can form hybrid dimmers. Characterisation of hybrid receptors in transfected cells. Biochem J 1990; 270:383-390. (Pubitemid 20273478)
5. Siddle K, Ursø B, Niesler CA, Cope DL, Molina L, Surinya KH, et al. Specificity in ligand binding and intracellular signaling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29 (Pt 4):513-525. (Pubitemid 32783649)
6. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990; 9:2409-2413.
7. Yamaguchi Y, Flier JS, Benecke H, Ransil BJ, Moller DE. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology 1993; 132:1132-1138. (Pubitemid 23068628)
8. Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM, Moller DE. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991; 129:2058-2066.
9. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology 2003; 144:2650-2658. (Pubitemid 36629918)
10. Serrano R, Villar M, Mart́inez C, Carrascosa JM, Gallardo N, Andrés A. Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. J Mol Endocrinol 2005; 34: 153-161. (Pubitemid 40305557)
11. Pandini G, Frasca F, Mineo R, Sciacca L,Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277:39684-39695. [Epub 22 July 2002]. (Pubitemid 35190951)
12. Belfiore A, Frasca F, Pandini G, Sciacca L,Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30:586-623. [Epub 14 September 2009].
13. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 2002; 87:245-254. (Pubitemid 34084698)
14. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288. (Pubitemid 29193789)
15. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999; 18:2471-2479. (Pubitemid 29206160)
16. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75:73-82. (Pubitemid 23306022)
17. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5:2503-2512.
18. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988; 263:11486-11492.
19. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007; 6:705-713. (Pubitemid 46535683)
20. Yamauchi K, Pessin JE. Insulin receptorsubstrate-1 (IRS1) and Shc compete for a limited pool of Grb2 in mediating insulin downstream signaling. J Biol Chem 1994; 269:31107-31114. (Pubitemid 24377605)
21. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19:7203-7215. (Pubitemid 29441900)
22. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97:12103-12108.
23. Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D, et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004; 83:161-170. (Pubitemid 38161263)
24. Zhang X, Lin M, Van Golen KL, Yoshioka K, Itoh K, Yee D. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 2005; 93:159-168. (Pubitemid 41396777)
25. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12. (Pubitemid 46206663)
26. Phillips LS, Pao CI, Villafuerte BC. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 1998; 60:195-265.
27. Albiston AL, Saffery R, Herington AC Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene. Endocrinology 1995; 136:696-704.
28. Blat C, Delbe J,Villaudy J, Chatelain G, Golde A, Harel L. Inhibitory diffusible factor 45 bifunctional activity. As a cell growth inhibitor and as an insulin-like growth factor I-binding protein. J Biol Chem 1989; 264:12449-12454. (Pubitemid 19191135)
29. Liu L, Delbé J, Blat C, Zapf J, Harel L. Insulin-like growth factor binding protein-3 (IGFBP-3), an inhibitor of serum growth factors other than IGF-I and-II. J Cell Physiol 1992; 153:15-21.
30. Martin JL, Weenink SM, Baxter RC. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factoraction in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogenactivated protein kinases. J Biol Chem 2003; 278:2969-2976. (Pubitemid 36801203)
31. Cohen P, Lamson G, Okajima T, Rosenfeld RG. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 1993; 7:380-386. (Pubitemid 23104526)
32. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-1396. (Pubitemid 28209997)
33. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, et al. Plasma insulin-like growth factor-I, insulin-like growth factor binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92:1910-1917. (Pubitemid 32036921)
34. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518. (Pubitemid 38868620)
35. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15:80-101. (Pubitemid 24058597)
36. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 2004; 279:339-359.
37. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57:4667-4672. (Pubitemid 27468963)
38. Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 1992; 22:101-106.
39. Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003; 35:836-842. (Pubitemid 38058191)
40. Cohen BD, Baker DA, Soderstrom C, Leininger JR, Travlos G, Wilson R, Barrett JC. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751 871. Clin Cancer Res 2005; 11:2063-2073. (Pubitemid 40471873)
41. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28:3009-3021.
42. Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007; 56:1638-1646. (Pubitemid 46842597)
43. Sepp-Lorenzino L. Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 1998; 47:235-253. (Pubitemid 28059820)
44. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5:221-230. (Pubitemid 38402114)
45. Garćia-Echeverŕia C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5:231-239. (Pubitemid 38402115)
46. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009; 8:2122-2130.
47. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:2337-2342.
48. Girnita A, Girnita L, Del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64:236-242. (Pubitemid 38114104)
49. Ekman S, Frödin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2010 (Early Online, 1-7).
50. Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000; 39:15705-15712. (Pubitemid 32038232)
51. Girnita A, Girnita L, Del Prete F, Bartolazzi A, Larsson O, Axelson M. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2010; 70:206-218.
52. Salisbury AJ, Macaulay VM. Development of molecular agents for IGF receptortargeting. Horm Metab Res 2003; 35:843-849. (Pubitemid 38058192)
53. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19:2189-2200. (Pubitemid 32366973)
54. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55:2463-2469.
55. Baserga R, Resnicoff M, D'Ambrosio C, Valentinis B. The role of the IGF-I receptor in apoptosis. Vitam Horm 1997; 53:65-98.
56. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998; 58:5432-5438. (Pubitemid 28551127)
57. Yavari K,Taghikhani M, Maragheh MG, Mesbah-Namin SA, Babaei MH, Arfaee AJ, et al. SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation. Acta Oncol 2010; 49:70-75.
58. Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX, Miao DS, et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009; 327:257-266.
59. Yavari K,Taghikhani M, Maragheh MG, Mesbah-Namin SA, Babaei MH. Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res 2009; 40:235-240.
60. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751 871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13:5834-5840. (Pubitemid 47583908)
61. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-8921. (Pubitemid 38064071)
62. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083. (Pubitemid 37022647)
63. Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF-IR) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol ASCO Annu Meet Proc 2008; 26: [Abstr 3520].
64. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumors (ST). J Clin Oncol ASCOAnnu Meet Proc 2008; 26: [Abstr 3582].
65. Dong J, Tamraz S, Berquist L, Boccia A, Sereno A, Chu P, et al. BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and rapamycin in sarcoma cell lines. Proc Annu Meet Am Assoc Cancer Res. 2008, [Abstr 4002].
66. Seraj J, Tsai M, Sieberling M, Cutler D. Evaluating the safety and pharmacokinetics of afully human IGF-1 receptorantibody,SCH 717454, in healthy volunteers. Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, San Francisco, USA, 22-26 October 2007, http://www.aacr.org/uploads/DocumentRepository/2007conf/moltar/mt07-postera.pdf.
67. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol ASCO Annu Meet Proc 2007; 25: [Abstr 3590].
68. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, et al. A recombinant humanized anti-insulin-like growth factor receptortype I antibody (h7C10) enhances the antitumor activity ofvinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113:316-328. (Pubitemid 39628325)
69. Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005; 4:1214-1221. (Pubitemid 41149569)
70. Mulvihill M, Qun-Sheng J, Rosenfeld-Franklin M, Buck E, Cooke A, Eyzaguirre A, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-1171.
71. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009; 8:3341-3349.
72. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-371. (Pubitemid 43166043)
73. Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, et al. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005; 48:5639-5643. (Pubitemid 41298335)
74. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10:1041-1047. (Pubitemid 41074142)
75. Aftab DT. Simultaneous inhibition of IGF-1R and Src family kinases causes tumor growth inhibition and tumor regression in xenograft models. Eur J Cancer Suppl 2006; 4:178.
76. Cappuzzo F,Toschi L,Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGF-1) is significantly associated with longer survival in non-small cell lung cancer patients treated with gefitinib. Ann Oncol 2006; 17:1120-1127. (Pubitemid 43985248)
77. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99:83-89. (Pubitemid 351920237)
78. Fidler MJ, Basu S, Buckingham L, Kaiser K, McCormack SE, Coon JS, et al. Insulin-like growth factor receptor 1 (IGF-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib. J Clin Oncol ASCO Annu Meet Proc 2008; 26: [Abstr 8036].
79. Cappuzzo F,Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small cell lung cancer (NSCLC) patients. Ann Oncol 2010; 21:562-567.
80. De Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007; 13:3611-3616. (Pubitemid 46955123)